tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SE:CANTA Stock Latest News

Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
RatingsCantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
1d ago
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
PremiumCompany Announcements
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
2d ago
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
PremiumCompany Announcements
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
16d ago
Cantargia to Engage Investors at Leerink Global Healthcare Conference
PremiumCompany Announcements
Cantargia to Engage Investors at Leerink Global Healthcare Conference
25d ago
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
PremiumRatings
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
29d ago
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
PremiumCompany AnnouncementsCantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
30d ago
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
Premium
Ratings
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
3M ago
Cantargia Reports TRIFOUR Study Results on Nadunolimab
Premium
Company Announcements
Cantargia Reports TRIFOUR Study Results on Nadunolimab
3M ago
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
PremiumRatings
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
3M ago
Cantargia AB Releases Interim Report Highlighting Strategic Progress
PremiumCompany Announcements
Cantargia AB Releases Interim Report Highlighting Strategic Progress
3M ago
Cantargia AB Announces Nomination Committee for 2026 AGM
PremiumCompany Announcements
Cantargia AB Announces Nomination Committee for 2026 AGM
3M ago
Cantargia AB to Release Interim Report and Host Investor Presentation
PremiumCompany Announcements
Cantargia AB to Release Interim Report and Host Investor Presentation
4M ago
Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating
PremiumRatingsCantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating
4M ago
Cantargia AB to Present at Key Investor Conferences
Premium
Company Announcements
Cantargia AB to Present at Key Investor Conferences
4M ago
Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus
Premium
Company Announcements
Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus
5M ago
Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million
PremiumCompany Announcements
Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million
5M ago
Cantargia Secures US Patent for Nadunolimab, Boosting Market Position
PremiumCompany Announcements
Cantargia Secures US Patent for Nadunolimab, Boosting Market Position
6M ago
Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development
PremiumCompany Announcements
Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development
6M ago
Cantargia AB Appoints Dr. Hilde Steineger as New CEO
PremiumCompany Announcements
Cantargia AB Appoints Dr. Hilde Steineger as New CEO
6M ago
Cantargia AB to Release H1 2025 Interim Report with Investor Presentation
PremiumCompany AnnouncementsCantargia AB to Release H1 2025 Interim Report with Investor Presentation
6M ago
Cantargia Reports Preliminary Phase 2 Results for Nadunolimab in TNBC
Premium
Company Announcements
Cantargia Reports Preliminary Phase 2 Results for Nadunolimab in TNBC
7M ago
Cantargia’s Nadunolimab Shows Promise in Advanced Lung Cancer Trial
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Advanced Lung Cancer Trial
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >